Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HRL heads into early October with the stock near multi-year lows, a director buying the dip with his own cash, and BNP Paribas trimming its target again just this week, a split verdict that captures the tension around Hormel's recovery story.
The clearest new development is on the insider side. Director William Newlands made an open-market purchase of 10,000 shares on October 5 at $20.10, spending $201,000 of his own money without a pre-arranged 10b5-1 plan. That is a discretionary buy, not a compensation mechanism, and it stands out against the 90-day net picture, which is marginally negative at roughly $294,000 in net sales, driven mainly by a July disposal from a different director. The September 30 transactions were routine equity grants, not open-market purchases, so Newlands' buy is the only genuine conviction signal in recent weeks.
Short positioning has been stable since the step-up documented last week. Short interest remains at 3.8% of the free float, with the month-over-month increase of roughly 22% now consolidated rather than accelerating. The borrow market offers no friction to bears: the cost to borrow has eased over the past week to 0.41%, and availability runs at around 1,056%, more than ten shares available to lend for every one already borrowed. There is no mechanical pressure on short sellers here. Options positioning is likewise unremarkable, with the put/call ratio at 0.51, almost exactly in line with its 20-day average and nowhere near the defensive extremes of late September, when the ratio briefly touched 0.67.
The Street remains neutral and is edging lower on its numbers. BNP Paribas cut its target today from $26 to $23, maintaining a Neutral rating. That follows a prior cut in August, also from BNP, and a JP Morgan raise to $26 back in mid-August. The consensus mean target sits near $26, implying roughly 30% upside from the current $19.88 price. The bull case centres on six consecutive quarters of organic sales growth, portfolio simplification toward higher-margin brands, and durable foodservice momentum. Bears point to retail volume falling 3.9% despite modest price gains, pork processing margins down more than 6% year-on-year, and commodity exposure that makes earnings quality lumpy. Valuation has compressed: the price-to-earnings multiple has dropped about 1.2 points over 30 days to 12.8x, and EV/EBITDA has fallen to 9.3x. The dividend score ranks in the 98th percentile of the universe, reflecting the yield at current levels, though the dividend history in the data is stale and should not be relied on for the current rate.
Retail attention has ticked up. Wikipedia views and ORTEX page traffic are running about 1.3 standard deviations above the prior 90-day average, a modest attention signal with no measured link to fundamentals.
The August earnings print is the relevant historical reference point. The stock fell 9% in a single session on August 27 and lost a further 8.6% over the following five days, the sharpest single-print reaction in the available data. The next scheduled release is December 3, giving the stock 57 days to either stabilise or drift further before the next hard test of the recovery thesis. Newlands' purchase and the Street's still-open price targets say one thing; the continuing short build and BNP's second consecutive target cut say another, and the December print is where those views collide.
See the live data behind this article on ORTEX.
Open HRL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
